Dr. Mark Schumacher is a Professor of Anesthesiology at the University of California, San Francisco with a clinical, research and educational focus on pain management. He is currently Medical Director of Pain Services at UCSF Medical Center and Division Chief of Pain Medicine in the Department of Anesthesia. Dr. Schumacher was the PI for a recent NIH award in 2012 to establish a Center of Excellence in Pain Education at UCSF.
Dr. Schumacher has expertise in opioid and non-opioid strategies in pain control and has worked successfully to introduce multidisciplinary pain care and non-opioid analgesic strategies at UCSF Medical Center. His scientific achievements include being part of the team that isolated the Capsaicin Receptor – TRPV1, a major target in the development of non-opioid analgesic therapies.
- Miaskowski C, Mastick J, Paul SM, Topp K, Smoot B, Abrams G, Chen LM, Kober KM, Conley YP, Chesney M, Bolla K, Mausisa G, Mazor M, Wong M, Schumacher M, Levine JD. Chemotherapy-Induced Neuropathy in Cancer Survivors. J Pain Symptom Manage. 2017 Jan 04.
- Guan Z, Hellman J, Schumacher M. Contemporary views on inflammatory pain mechanisms: TRPing over innate and microglial pathways. F1000Res. 2016; 5.
- Zavala K, Lee J, Chong J, Sharma M, Eilers H, Schumacher MA. The anticancer antibiotic mithramycin-A inhibits TRPV1 expression in dorsal root ganglion neurons. Neurosci Lett. 2014 Aug 22; 578:211-6.
- Schumacher MA. Back pain and the mineralocorticoid receptor: is there a connection? Anesthesiology. 2012 Nov; 117(5):951-2.
- Chu C, Zavala K, Fahimi A, Lee J, Xue Q, Eilers H, Schumacher MA. Transcription factors Sp1 and Sp4 regulate TRPV1 gene expression in rat sensory neurons. Mol Pain. 2011; 7:44.
- Turnbull JH, Gebauer SL, Miller BL, Barbaro NM, Blanc PD, Schumacher MA. Cutaneous nerve transection for the management of intractable upper extremity pain caused by invasive squamous cell carcinoma. J Pain Symptom Manage. 2011 Jul; 42(1):126-33.